Tag: Harm reduction

Lessons learned from the HCV Symposium Part 2: Equal access, equal representation

By Sarah Cloutier and Yung-Wo Jao

On February 27, 2016 CATIE had the opportunity to host another Learning Institute (LI) at the 5th Canadian Symposium on HCV in Montreal, Quebec.  Learning Institutes are exciting knowledge-exchange and capacity-building opportunities for stakeholders engaged in Hep C prevention, treatment and care across Canada. Our 15 rapporteurs learned about current research and worked together to summarize that information and bring it back to their communities. 

 In part two of this two-part blog series, two rapporteurs reflect on their experiences at the LI.

Lessons learned from the HCV Symposium Part 1: Blinders off, and who cleans up after the fight?

By Leona Quewezance and Stephanie Massey

On February 27, 2016 CATIE had the opportunity to host another Learning Institute (LI) at the 5th Canadian Symposium on HCV in Montreal, Quebec. Learning Institutes are exciting knowledge-exchange and capacity-building opportunities for stakeholders engaged in Hep C prevention, treatment and care across Canada. Our 15 rapporteurs learned about current research and worked together to summarize that information and bring it back to their communities.

In part one of this two-part blog series, two rapporteurs reflect on their experiences at the LI.

Six ways to make harm reduction work in Canada’s prisons

By Emily van der Meulen and Sandra Ka Hon Chuemily

sandraIn Canada today, prisoners who inject drugs need to share needles, many of which have been used numerous times by other prisoners. Without access to sterile injection equipment, rates of HIV and hepatitis C virus are much higher behind bars than in the broader community. Prison-based needle and syringe programs (PNSPs) are an important way to address this public health problem, yet Canadian correctional authorities often claim they won’t work. A recent study demonstrates that PNSPs are indisputably feasible in Canada and should be implemented now.

A new report, On Point: Recommendations for Prison-Based Needle and Syringe Programs in Canada, outlines the findings of a two-year study that involved consultation with a range of diverse stakeholders, including former prisoners themselves. The research was conducted by representatives from the Department of Criminology at Ryerson University, PASAN (a community-based AIDS service organization that provides community development, education, and support to prisoners and ex-prisoners in Ontario), and the Canadian HIV/AIDS Legal Network (one of the world’s leading organizations tackling the legal and human rights issues related to HIV).

Supervised injection in Toronto will improve the health of people who inject drugs

By Drs. Ahmed Bayoumi and Carol Strike

bayoumi-330-220 carol-strike

Over the past year, advocates or elected officials in Montreal, Ottawa, Victoria, Baltimore, New York City, Ithaca (NY), Seattle, San Francisco, Glasgow and four cities in Ireland have called  for the implementation of supervised injection services. More recently, Toronto’s Medical Officer of Health Dr. David McKeown recommended that the Board of Health start a community consultation process toward establishing supervised injection services within three existing facilities in the city. The Board voted unanimously in favour.  As the lead investigators of the TOSCA study  (the Toronto and Ottawa Supervised Consumption Assessment), we support Dr. McKeown’s proposal and look forward to the opening of these services in Toronto.

Health Canada’s statement on the status of naloxone is a welcome drug policy paradigm shift

By Dr. Lynne LeonardLynne Leonard pic

The administration of naloxone, a chemical compound that effectively temporarily reverses the effects of an opioid overdose, is recommended by the World Health Organization to be used in the case of an opioid overdose. Naloxone is currently available in Canada only in an injectable form and by prescription only; it can only be administered to the person named on the prescription, not to a third party. With the objective of making naloxone more widely available in Canada to address the growing number of opioid overdoses, and consequent on a review of health and safety data, Health Canada has suggested an amendment to the prescription drug list to allow non-prescription use of naloxone specifically for emergency use for opioid overdose outside hospital settings. A public consultation on the proposal has been initiated and if the change in status continues to be supported by consultation evidence, the change will be finalized.